AstraZeneca completes global license agreement for ZEGFROVY in lung cancer
AstraZeneca has completed a global license agreement for oral EGFR inhibitor ZEGFROVY (sunvozertinib) for lung cancer.
Story updates
11:00:49 AM UTC
SquawkNews
AstraZeneca today announced the successful completion of the previously announced exclusive license agreement with Dizal Pharmaceutical Co., Ltd for ZEGFROVY® (sunvozertinib), an oral irreversible epidermal growth factor receptor (EGFR) inhibitor for patients with lung cancer. Through this agreemen…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.